A new study from the National Bureau of Economic Research (NBER) suggests that middle-aged adults using GLP-1 drugs for obesity could save over $192,000 in lifetime medical costs. These savings are even higher for individuals without college degrees, potentially reaching $220,000. The drugs' effectiveness in treating obesity directly, rather than relying solely on diet and exercise, makes them particularly beneficial for those with time constraints or lower socioeconomic status. AI
IMPACT GLP-1 drugs may significantly reduce long-term healthcare expenditures, particularly for lower-income populations, potentially altering market dynamics and patient access strategies.
RANK_REASON The cluster reports on findings from a new study published by the National Bureau of Economic Research (NBER) regarding the economic impact of GLP-1 drugs. [lever_c_demoted from research: ic=1 ai=0.4]
- Eli Lilly
- Fatima Cody Stanford
- Felipe Montano-Campos
- GLP-1
- Massachusetts General Hospital
- National Bureau of Economic Research
- Novo Nordisk
- Wegovy
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
